
Rhythm Pharmaceuticals, Inc.: shareholders and insiders
Price
$116.61
November 17, 2026Market cap $8.0B
What Ploutos Investor adds for Rhythm Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 35% since Nov 3, 2026, when the 10-Q these figures come from was filed ($86.44 then, $116.61 on Nov 17, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 18, 2025 to Sep 14, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$36M
9 people
From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan97%
- The rest3%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $36M by 8 people
- 2025: no buys, sold $723.6K by 1 person
- 2026: no buys, sold $36M by 8 people
- Sep 14, 2026David P MeekerPresident and CEOKind10b5-1
- Sep 14, 2026David P MeekerPresident and CEOKind10b5-1
- Sep 14, 2026David P MeekerPresident and CEOKind10b5-1
- Sep 14, 2026David P MeekerPresident and CEOKind10b5-1
- Sep 14, 2026David P MeekerPresident and CEOKind10b5-1
- Sep 14, 2026David P MeekerPresident and CEOKind10b5-1
- Aug 31, 2026Hunter C SmithChief Financial OfficerKind10b5-1
- Aug 31, 2026Hunter C SmithChief Financial OfficerKind10b5-1
- Aug 31, 2026Hunter C SmithChief Financial OfficerKind10b5-1
- Aug 31, 2026Hunter C SmithChief Financial OfficerKind10b5-1
- Aug 13, 2026Joseph ShulmanChief Technical OfficerKind10b5-1
- Aug 13, 2026Joseph ShulmanChief Technical OfficerKind10b5-1
- Aug 13, 2026Alastair GarfieldChief Scientific OfficerKind10b5-1
- Aug 13, 2026Alastair GarfieldChief Scientific OfficerKind10b5-1
- Aug 13, 2026Alastair GarfieldChief Scientific OfficerKind10b5-1
- Aug 13, 2026Alastair GarfieldChief Scientific OfficerKind10b5-1
- Aug 13, 2026Jennifer Kayden LeeEVP, Head of North AmericaKind10b5-1
- Aug 13, 2026Jennifer Kayden LeeEVP, Head of North AmericaKind10b5-1
- Aug 13, 2026Jennifer Kayden LeeEVP, Head of North AmericaKind10b5-1
- Aug 12, 2026Yann MazabraudEVP, Head of InternationalKind10b5-1
- Aug 12, 2026Yann MazabraudEVP, Head of InternationalKind10b5-1
- Aug 12, 2026Yann MazabraudEVP, Head of InternationalKind10b5-1
- Aug 12, 2026Yann MazabraudEVP, Head of InternationalKind10b5-1
- Aug 12, 2026Yann MazabraudEVP, Head of InternationalKind10b5-1
- Aug 12, 2026Yann MazabraudEVP, Head of InternationalKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | David P MeekerPresident and CEO | 10b5-1 | 50.0K | $6.05 | $302.5K | Form 4 |
| Sep 14, 2026 | David P MeekerPresident and CEO | 10b5-1 | 6,439 | $101.75 | $655.1K | Form 4 |
| Sep 14, 2026 | David P MeekerPresident and CEO | 10b5-1 | 30.7K | $102.35 | $3.1M | Form 4 |
| Sep 14, 2026 | David P MeekerPresident and CEO | 10b5-1 | 8,698 | $103.43 | $899.6K | Form 4 |
| Sep 14, 2026 | David P MeekerPresident and CEO | 10b5-1 | 1,817 | $104.55 | $190.0K | Form 4 |
| Sep 14, 2026 | David P MeekerPresident and CEO | 10b5-1 | 2,300 | $105.19 | $241.9K | Form 4 |
| Aug 31, 2026 | Hunter C SmithChief Financial Officer | 10b5-1 | 57.2K | $25.79 | $1.5M | Form 4 |
| Aug 31, 2026 | Hunter C SmithChief Financial Officer | 10b5-1 | 23.1K | $104.59 | $2.4M | Form 4 |
| Aug 31, 2026 | Hunter C SmithChief Financial Officer | 10b5-1 | 11.5K | $105.37 | $1.2M | Form 4 |
| Aug 31, 2026 | Hunter C SmithChief Financial Officer | 10b5-1 | 28.2K | $106.20 | $3.0M | Form 4 |
| Aug 13, 2026 | Joseph ShulmanChief Technical Officer | 10b5-1 | 2,024 | $6.80 | $13.8K | Form 4 |
| Aug 13, 2026 | Joseph ShulmanChief Technical Officer | 10b5-1 | 5,079 | $119.75 | $608.2K | Form 4 |
| Aug 13, 2026 | Alastair GarfieldChief Scientific Officer | 10b5-1 | 2,007 | $116.11 | $233.0K | Form 4 |
| Aug 13, 2026 | Alastair GarfieldChief Scientific Officer | 10b5-1 | 1,556 | $117.08 | $182.2K | Form 4 |
| Aug 13, 2026 | Alastair GarfieldChief Scientific Officer | 10b5-1 | 3,400 | $118.28 | $402.2K | Form 4 |
| Aug 13, 2026 | Alastair GarfieldChief Scientific Officer | 10b5-1 | 800 | $119.17 | $95.3K | Form 4 |
| Aug 13, 2026 | Jennifer Kayden LeeEVP, Head of North America | 10b5-1 | 35.0K | $24.29 | $850.2K | Form 4 |
| Aug 13, 2026 | Jennifer Kayden LeeEVP, Head of North America | 10b5-1 | 21.6K | $6.80 | $146.9K | Form 4 |
| Aug 13, 2026 | Jennifer Kayden LeeEVP, Head of North America | 10b5-1 | 75.8K | $117.38 | $8.9M | Form 4 |
| Aug 12, 2026 | Yann MazabraudEVP, Head of International | 10b5-1 | 46.6K | $6.80 | $317.1K | Form 4 |
| Aug 12, 2026 | Yann MazabraudEVP, Head of International | 10b5-1 | 2,300 | $111.80 | $257.1K | Form 4 |
| Aug 12, 2026 | Yann MazabraudEVP, Head of International | 10b5-1 | 1,000 | $112.86 | $112.9K | Form 4 |
| Aug 12, 2026 | Yann MazabraudEVP, Head of International | 10b5-1 | 3,605 | $114.70 | $413.5K | Form 4 |
| Aug 12, 2026 | Yann MazabraudEVP, Head of International | 10b5-1 | 14.6K | $115.43 | $1.7M | Form 4 |
| Aug 12, 2026 | Yann MazabraudEVP, Head of International | 10b5-1 | 18.2K | $116.49 | $2.1M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 24, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by RYTM's officers and directors from 2017 up to November 17, 2025, 9 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 4 more, back to 2017
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- RA Capital Management, L.P.with 3 more personsShare of class9.90%
- Baker Bros. Advisors LPwith 3 more personsShare of class8.90%
- BlackRock, Inc.Share of class6.90%
- Primecap ManagementCOMShare of class5.21%
- JPMorgan ChaseShare of class5.10%
- Perceptive Advisors LLCwith 3 more personsShare of class5.10%
- Vanguard Capital ManagementShare of class5.02%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P.with 3 more persons | 9.90% | 6.67M | Feb 17, 20262 filings since Aug 14, 2025 | 13G/A | |
| Baker Bros. Advisors LPwith 3 more persons | 8.90% | 5.60M | May 15, 2025 | 13G/A | |
| BlackRock, Inc. | 6.90% | 4.36M | Apr 24, 2025 | 13G/A | |
| Primecap ManagementCOM | 5.21% | 3.48M | Feb 12, 20265 filings since Feb 13, 2025 | 13G/A | |
| JPMorgan Chase | 5.10% | 3.56M | Oct 13, 2026 | 13G | |
| Perceptive Advisors LLCwith 3 more persons | 5.10% | 3.52M | May 15, 20262 filings since May 15, 2025 | 13G/A | |
| Vanguard Capital Management | 5.02% | 3.43M | Apr 30, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Duquesne (Druckenmiller)In the quarter+33%
- Point72 (Cohen)In the quarter+75%
- Bridgewater (Dalio)In the quarter
- Citadel Advisors (Griffin)In the quarter-75%
- Millennium Mgmt (Englander)In the quarter-0.3%
- Renaissance TechnologiesIn the quarter+30%
- D.E. ShawIn the quarter-24%
- AQR CapitalIn the quarter+15%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Duquesne (Druckenmiller) | 269.9K | +33% | $26M | 0.62% |
| Point72 (Cohen) | 726.5K | +75% | $69M | 0.11% |
| Bridgewater (Dalio) | 95.1K | $9.1M | 0.04% | |
| Citadel Advisors (Griffin) | 317.0K | -75% | $30M | 0.02% |
| Millennium Mgmt (Englander) | 315.7K | -0.3% | $30M | 0.02% |
| Renaissance Technologies | 88.7K | +30% | $8.4M | 0.01% |
| D.E. Shaw | 22.8K | -24% | $2.2M | 0.00% |
| AQR Capital | 68.2K | +15% | $6.5M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 16.1% of its shares outstanding were held short, +2.2% since the report before.
- Shares held short
- 11.00M
- 16.1%
- Since the report before10.77M on Sep 30, 2026
- +2.2%
- 13.5
- 816.3K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 97%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 11.65M
- Nov 15, 2023: Shares held short 9.41M
- Nov 30, 2023: Shares held short 9.25M
- Dec 15, 2023: Shares held short 8.64M
- Dec 29, 2023: Shares held short 8.14M
- Jan 12, 2024: Shares held short 8.45M
- Jan 31, 2024: Shares held short 8.86M
- Feb 15, 2024: Shares held short 8.76M
- Feb 29, 2024: Shares held short 9.00M
- Mar 15, 2024: Shares held short 9.20M
- Mar 28, 2024: Shares held short 9.74M
- Apr 15, 2024: Shares held short 10.20M
- Apr 30, 2024: Shares held short 10.59M
- May 15, 2024: Shares held short 10.32M
- May 31, 2024: Shares held short 10.92M
- Jun 14, 2024: Shares held short 11.04M
- Jun 28, 2024: Shares held short 9.24M
- Jul 15, 2024: Shares held short 10.07M
- Jul 31, 2024: Shares held short 10.18M
- Aug 15, 2024: Shares held short 9.88M
- Aug 30, 2024: Shares held short 9.64M
- Sep 13, 2024: Shares held short 9.34M
- Sep 30, 2024: Shares held short 8.23M
- Oct 15, 2024: Shares held short 8.46M
- Oct 31, 2024: Shares held short 8.36M
- Nov 15, 2024: Shares held short 6.71M
- Nov 29, 2024: Shares held short 6.37M
- Dec 13, 2024: Shares held short 5.81M
- Dec 31, 2024: Shares held short 5.27M
- Jan 15, 2025: Shares held short 5.45M
- Jan 31, 2025: Shares held short 5.13M
- Feb 14, 2025: Shares held short 5.41M
- Feb 28, 2025: Shares held short 5.15M
- Mar 14, 2025: Shares held short 4.71M
- Mar 31, 2025: Shares held short 4.66M
- Apr 15, 2025: Shares held short 5.11M
- Apr 30, 2025: Shares held short 4.85M
- May 15, 2025: Shares held short 5.07M
- May 30, 2025: Shares held short 4.78M
- Jun 13, 2025: Shares held short 4.76M
- Jun 30, 2025: Shares held short 4.85M
- Jul 15, 2025: Shares held short 4.79M
- Jul 31, 2025: Shares held short 4.51M
- Aug 15, 2025: Shares held short 4.67M
- Aug 29, 2025: Shares held short 4.97M
- Sep 15, 2025: Shares held short 5.22M
- Sep 30, 2025: Shares held short 5.58M
- Oct 15, 2025: Shares held short 5.57M
- Oct 31, 2025: Shares held short 5.23M
- Nov 14, 2025: Shares held short 5.50M
- Nov 28, 2025: Shares held short 5.52M
- Dec 15, 2025: Shares held short 5.58M
- Dec 31, 2025: Shares held short 6.20M
- Jan 15, 2026: Shares held short 6.29M
- Jan 30, 2026: Shares held short 6.24M
- Feb 13, 2026: Shares held short 6.02M
- Feb 27, 2026: Shares held short 6.32M
- Mar 13, 2026: Shares held short 6.54M
- Mar 31, 2026: Shares held short 7.62M
- Apr 15, 2026: Shares held short 7.83M
- Apr 30, 2026: Shares held short 8.06M
- May 15, 2026: Shares held short 8.28M
- May 29, 2026: Shares held short 7.91M
- Jun 15, 2026: Shares held short 8.01M
- Jun 30, 2026: Shares held short 9.67M
- Jul 15, 2026: Shares held short 9.57M
- Jul 31, 2026: Shares held short 9.44M
- Aug 14, 2026: Shares held short 10.15M
- Aug 31, 2026: Shares held short 10.30M
- Sep 15, 2026: Shares held short 10.29M
- Sep 30, 2026: Shares held short 10.77M
- Oct 15, 2026: Shares held short 11.00M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading55.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 55.7% of the shares in the reported trades were short sales, against 67.5% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 55.7%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 67.5%
- Change
- -11.8 pts
- Short sales a dayon average, of 1.14M shares
- 636.0K
- More than atof 3,666 US-listed companies, same days
- 70%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 75.5%
- Oct 12, 2026: Short sales 44.3%
- Oct 13, 2026: Short sales 72.4%
- Oct 14, 2026: Short sales 55.2%
- Oct 15, 2026: Short sales 62.2%
- Oct 16, 2026: Short sales 71.7%
- Oct 19, 2026: Short sales 62.7%
- Oct 20, 2026: Short sales 84.2%
- Oct 21, 2026: Short sales 74.5%
- Oct 22, 2026: Short sales 51.9%
- Oct 23, 2026: Short sales 59.8%
- Oct 26, 2026: Short sales 45.1%
- Oct 27, 2026: Short sales 68.7%
- Oct 28, 2026: Short sales 58.2%
- Oct 29, 2026: Short sales 63.8%
- Oct 30, 2026: Short sales 70.2%
- Nov 2, 2026: Short sales 75.2%
- Nov 3, 2026: Short sales 68.4%
- Nov 4, 2026: Short sales 50%
- Nov 5, 2026: Short sales 60.9%
- Nov 6, 2026: Short sales 47%
- Nov 9, 2026: Short sales 50.5%
- Nov 10, 2026: Short sales 55.2%
- Nov 11, 2026: Short sales 40.5%
- Nov 12, 2026: Short sales 29.4%
- Nov 13, 2026: Short sales 32.2%
- Nov 16, 2026: Short sales 31.9%
- Nov 17, 2026: Short sales 51.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- David P MeekerPresident and CEODirectly241.6K
- Hunter C SmithChief Financial OfficerDirectly114.0K
- Yann MazabraudEVP, Head of InternationalDirectly105.8K
- Pamela J. CramerChief Human Resources OfficerDirectly20.8K
- Joseph ShulmanChief Technical OfficerDirectly15.9K
- Lynn A. TetraultDirectorDirectly11.7K
- David W J McgirrDirectorDirectly11.7K
- Jennifer L GoodDirectorDirectly11.7K
- Christophe JeanDirectorDirectly11.7K
- Stuart A ArbuckleDirectorDirectly11.7K
- Alastair GarfieldChief Scientific OfficerDirectly3,095
- Jennifer Kayden LeeEVP, Head of North AmericaDirectly–
- Christopher Paul GermanCorporate Controller & CAODirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| David P MeekerPresident and CEO | 241.6K | – | Sep 14, 2026 | Form 4 |
| Hunter C SmithChief Financial Officer | 114.0K | – | Aug 31, 2026 | Form 4 |
| Yann MazabraudEVP, Head of International | 105.8K | – | Aug 12, 2026 | Form 4 |
| Pamela J. CramerChief Human Resources Officer | 20.8K | – | Dec 11, 2025 | Form 4 |
| Joseph ShulmanChief Technical Officer | 15.9K | – | Aug 13, 2026 | Form 4 |
| Lynn A. TetraultDirector | 11.7K | – | Jun 23, 2026 | Form 4 |
| David W J McgirrDirector | 11.7K | – | Jun 23, 2026 | Form 4 |
| Jennifer L GoodDirector | 11.7K | – | Jun 23, 2026 | Form 4 |
| Christophe JeanDirector | 11.7K | – | Jun 23, 2026 | Form 4 |
| Stuart A ArbuckleDirector | 11.7K | – | Jun 23, 2026 | Form 4 |
| Alastair GarfieldChief Scientific Officer | 3,095 | – | Aug 13, 2026 | Form 4 |
| Jennifer Kayden LeeEVP, Head of North America | – | – | Aug 13, 2026 | Form 4 |
| Christopher Paul GermanCorporate Controller & CAO | – | – | May 15, 2026 | Form 4 |
A lower bound: it counts only the 13 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.20%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.79%
- IBBiShares Biotechnology ETFWeight in the fund0.57%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.37%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.21%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.21%
- IWMiShares Russell 2000 ETFWeight in the fund0.19%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.19%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.14%
- JGROJPMorgan Active Growth ETFWeight in the fund0.11%
20 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 265
- Q4 2025: Managers 281
- Q1 2026: Managers 288
- Q2 2026: Managers 303
Institutional investors by quarter
The fund managers holding RYTM, quarter by quarter, from Q4 2017 to Q2 2025, 31 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 303 managers held 77.41M shares, worth $8.6B. During the quarter 63 opened a position, 48 closed one, 102 added and 99 trimmed.
The largest holders, Q2 2026
- Ra Capital ManagementIn the quarter
- BlackRockIn the quarter-1.3%
- Baker Bros. AdvisorsIn the quarter
- Primecap ManagementIn the quarter-7.3%
- Vanguard Portfolio ManagementIn the quarter+3.2%
- Vanguard Capital ManagementIn the quarter+1.3%
- JPMorgan ChaseIn the quarter+71%
- Perceptive AdvisorsIn the quarter+9.0%
- State StreetIn the quarter+13%
- Price T Rowe AssociatesIn the quarter+55%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Ra Capital Management | 6.67M | $740M | |
| BlackRock | 6.16M | -1.3% | $684M |
| Baker Bros. Advisors | 5.60M | $622M | |
| Primecap Management | 3.17M | -7.3% | $352M |
| Vanguard Portfolio Management | 3.14M | +3.2% | $348M |
| Vanguard Capital Management | 3.01M | +1.3% | $334M |
| JPMorgan Chase | 2.65M | +71% | $292M |
| Perceptive Advisors | 2.59M | +9.0% | $287M |
| State Street | 2.57M | +13% | $286M |
| Price T Rowe Associates | 2.57M | +55% | $285M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Rhythm Pharmaceuticals's filings show?
Who buys and sells is one part of Rhythm Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have RYTM's insiders bought or sold?
From Jun 24, 2026 to Sep 14, 2026 Rhythm Pharmaceuticals's insiders bought 0 and sold $33M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold RYTM?
8 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $69M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.